Posts by neonadmin
A Welcome Gift for the Pediatric Brain Tumor Community
What began as a proposal for a four-center US-based clinical trial of promising combination therapy for children battling brain tumors, has expanded into a large-scale clinical trial at 58 centers in 13 countries, that brings new hope to children across the globe.
Read MoreBrain Tumor Clinical Trial Now Enrolling Children
A Phase 1 clinical trial leveraging the re-engineered poliovirus is now open for enrollment to children 12 years and older at the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center. After years of following the progress of this promising therapy against adult glioblastoma and working with the research team on behalf of children, Solving Kids’ Cancer teamed up with The Andrew McDonough B+ Foundation to help move this forward in a trial for pediatric brain tumor patients.
Read MoreTargeted Therapy for Children with ALK-Driven Neuroblastoma
Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.
Read More“Lace Up for Kids” for Childhood Cancer Awareness Month
September is childhood cancer awareness month, and childhood cancer awareness is represented by the color gold. We are encouraging kids to swap out their shoelaces during the month of September and support kids fighting cancer by wearing gold.
Read MoreAdvocacy in Action
Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma.
Read MorePrecision Medicine Advances for Children With Neuroblastoma
Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.
Read MoreChildren with High Grade Brain Tumors will be able to Receive Cutting-edge Oncolytic Virus Therapy
The Andrew McDonough B+ Foundation (The B+ Foundation) and Solving Kids’ Cancer (SKC) presented a check for $208,500 to Dr. Matthias Gromeier and Dr. Eric Thompson at the Preston Robert Tisch Brain Tumor Center at Duke, to co-fund an exciting new immunotherapy trial for children with deadly brain tumors.
Read MoreThe Launch of an International Immunotherapy Trial for Children with Brain Tumors
A Kids’ Brain Tumor Cure Foundation, Solving Kids’ Cancer, and the Ty Louis Campbell (TLC) Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Read MoreSKC Formally Appeals NICE Decision
The National Institute for Health and Care Excellence (NICE) heard an appeal led by Solving Kids’ Cancer (SKC) against its recent decision to deny children in the UK treatment that is proven to significantly increase the chance of survival for children diagnosed with an aggressive childhood cancer, neuroblastoma.
Read MoreAccess to Cures Should Have No Borders
The British healthcare system has rejected an FDA/EMA-approved treatment proven to increase survival rates for children with cancer. NICE (National Institute for Health and Care Excellence) has rejected access to the drug across the UK, stating cost as the reason. However, when analyzing the real expense on taxpayers, the cost amounts to less than 3 pence per person, per year, in order to give these children access to the life-saving antibody.
Read More